Medtronic/$MDT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Medtronic

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.

Ticker

$MDT

Primary listing

NYSE

Industry

Health Care Equipment & Supplies

Headquarters

Galway, Ireland

Employees

95,000

ISIN

IE00BTN1Y115

Medtronic Metrics

BasicAdvanced
$110B
23.81
$3.61
0.81
$2.80
3.30%

What the Analysts think about Medtronic

Analyst ratings (Buy, Hold, Sell) for Medtronic stock.

Bulls say / Bears say

Medtronic's diabetes segment experienced an 8.4% sales increase in Q3 2025, driven by strong adoption of its insulin delivery systems, contributing to higher-than-expected profits. (reuters.com)
The company received FDA approval for the world's first adaptive deep brain stimulation system for Parkinson's patients, marking a significant advancement in personalized, sensing-enabled care. (prnewswire.com)
Medtronic announced plans to separate its diabetes business into a standalone company, aiming to unlock value and allow focused growth in this high-demand sector. (reuters.com)
Medtronic's medical surgical unit saw a 1.9% decline in sales to $2.07 billion in Q3 2025, missing estimates due to changed buying patterns and competitive pressures in the surgical staplers market. (reuters.com)
Analysts have recently lowered their price targets for Medtronic, with RBC Capital reducing its target to $101 from $105, indicating tempered expectations for the stock's performance. (markets.businessinsider.com)
The company's net income decreased by 2.12% year-over-year in Q3 2025, reflecting potential challenges in maintaining profitability amid operational pressures. (google.com)
Data summarised monthly by Lightyear AI. Last updated on 21 Jun 2025.

Medtronic Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Medtronic Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MDT

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

Jun27
Medtronic
Dividend·Ex-dividend
Jul11
Medtronic
Dividend·Payment
$0.71Per share
FAQs